NCT04158518Unknown不适用
De-escalation of Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Chaosu Hu1 个研究点 分布在 1 个国家目标入组 118 人开始时间: 2019年11月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 118
- 试验地点
- 1
- 主要终点
- DFS
研究概览
简要总结
The purpose of this study is to explore the efficacy and safety of image guided de-escalation protocols in patients with locoregionally advanced nasopharyngeal carcinoma (NPC). So the investigators studied whether toxicities reducing treatment with omitted concurrent chemotherapy after good response to induction chemotherapy would maintain survival outcomes while improving tolerability for patients with locoregionally advanced nasopharyngeal carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological diagnosis of nasopharyngeal carcinoma
- •Stage III or IVA according to UICC/AJCC 8th staging system
- •No prior anti-tumor treatment
- •Karnofsky Performance Score (KPS)≥70
- •Adequate blood supply
- •Informed consent obtained
排除标准
- •Can not take contrast-MRI imaging
- •Combined with other malignant tumor (except basal cell carcinoma of skin)
结局指标
主要结局
DFS
时间窗: 3 year
Disease Free Survival
次要结局
- OS(3 year)
研究者
Chaosu Hu
Principal Investigator
Fudan University
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 StudyBreast CancerNCT03820063Borstkanker Onderzoek Groep462
招募中
不适用
Image-guided radiochemotherapy in patients with pancreatic cancer using gold markers placed during endoscopic ultrasound.Patients with (borderline) resectable or locally advanced pancreatic cancer with an indication for radiochemotherapyNL-OMON23455Academic Medical Center Amsterdam50
招募中
2 期
Image-guided de-escalation of neoadjuvant chemotherapy in HER2-positive breast cancer: the TRAIN-3 study.HER2 positive breast cancer10006291breast cancerNL-OMON54506BOOG Study Center462
进行中（未招募）
1 期
Reducing the number chemotherapy cycles based on radiologic tumor response in HER2-positive breast cancer: the TRAIN-3 study (BOOG 2018-01)HER2-positive, stage II/III breast cancerMedDRA version: 20.0 Level: PT Classification code 10006200 Term: Breast cancer stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10006201 Term: Breast cancer stage III System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10075653 Term: HER2 gene amplification System Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2018-003275-35-NLBOOG Study Center462
终止
不适用
Pathological Validation of Functional Imaging in Head and Neck Squamous Cell CarcinomaHead and Neck CancerNCT01827709Universitaire Ziekenhuizen KU Leuven11